Global Media Strategies -- Your Brand, Your Audience

BioDelivery Sciences to host business update conference call and webcast on February 25

February 19, 2010 By: NCTechNews Category: Pharmaceuticals

(Raleigh, N.C.) BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced today that the Company will host a conference call and live webcast on Thursday, February 25, 2010 at 11:00 AM Eastern Time. Dr. Mark A. Sirgo, President & Chief Executive Officer and Dr. Andrew L. Finn, Executive Vice President of Product Development, will provide an update on the product portfolio, including development plans, anticipated timelines, partnership expectations and key upcoming milestones.

The agenda will include:

recent data from the Phase II study of BEMA Buprenorphine in dental pain;
clinical plans and timelines for BEMA Buprenorphine for pain and opioid dependence;
a review of recent pipeline additions including BEMA Granisetron; and
an update on the commercial launch of ONSOLIS (fentanyl buccal soluble film).
Interested parties may participate in the conference, including the question and answer session, by dialing 877-407-9039 (U.S. and Canada) or 201-689-8470 (international). The presentation and corresponding slides will be webcast live and can be accessed at www.bdsi.com. For those who are not available to listen to the live broadcast, the presentation will be archived.  

BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet needs in the areas of pain management and oncology supportive care. BDSI’s pain franchise currently consists of two products utilizing the Company’s patented BEMA buccal soluble film technology: ONSOLIS (fentanyl buccal soluble film) which was approved by FDA on July 16, 2009, for the management of breakthrough pain in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain, and BEMA Buprenorphine, an analgesic in Phase 2 clinical development with at least one potential target indication for the treatment of moderate to severe pain. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting and migraine. The Company is also working with its patented Bioral cochleate technology to facilitate oral dosing of drugs otherwise given by intravenous administration. The first product under development using the technology is Bioral Amphotericin B. The Company’s headquarters is located in Raleigh, North Carolina. For more information please visit www.bdsi.com.

Comments are closed.

← Talecris Biotherapeutics receives Health Canada approval for PROLASTIN®-C
New white paper reports the five essentials for minimizing clinical development risk →

  • Controlling Quality
    An RTP firm is gaining international notoriety as a leader in analytical instrumentation for the pharmaceutical and chemical manufacturing industries, sharing innovative solutions to evolving pharmaceutical and chemical manufacturing challenges, presenting on emerging multi-variant approaches to obtaining immediate, unambiguous results from drug product samples at a recent major international tradeshow.

    Portable Power
    Alternative energy solutions provider INI Power Systems, Inc. recently marked its ten-year anniversary by unveiling the innovative new Trinity™ series of portable alternative energy hybrid solutions at two major events catering to the defense and emergency first responder marketplaces, with attendees searching for reliable, flexible power systems with multiple applications.

    EV Innovation
    Morrisville-based green transportation pioneer Evatran™ recently hosted a demonstration of its Plugless Power™ hands-free electric vehicle (EV) charging system, showcasing cost savings and convenience of EV usage in residential, commercial and public applications.

    guide to success
    Entrepreneurs now have a workbook to guide them through successful implementation of business building blocks thanks to a new goal-setting toolkit for personal and professional success available at no charge from a Cary-based international strategic business consultant.

    Packaging Cures
    RTP-based advertising and branding firm The Marketing Machine helped overcome the issue of illiteracy among medical patients in Ghana, South Africa in designing packaging for the only manufacturer of anti-retroviral drugs in the region, creating individual icons and colors to help patients understand which drugs they needed, regardless of their ability to read.

    Broadband Stimulus
    Two grants funded by the American Recovery and Reinvestment Act are being used by MCNC to expand broadband connectivity and services throughout North Carolina and create more than 1,000 engineering and construction jobs, the organization said.

  • Recent Headlines

















free web site traffic and promotion